Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
(WorldNews Switzerland)

At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4 neurologic events occurred in 12% of patients; Grade 3/4 CRS occurred in 23% of treated patients using the Penn Grading Scale and was managed by protocol-specific algorithm More than a quarter of patients received Kymriah in outpatient setting during JULIET trial Cost-effectiveness and societal value of Kymriah in pediatric and young adult patients with r/r B-cell ALL to be presented at ASH The digital press release with multimedia content can be accessed here: Basel, December 10, 2017- Novartis today...